Navigation Links
EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board

EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board -- VIENNA, Austria, September 2, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements Click to view news release full screen  

EUCODIS Bioscience Appoints Two Industry Executives to Realigned Advisory Board


VIENNA, Austria, September 2, 2010 /PRNewswire/ -- EUCODIS Bioscience, a developer and manufacturer of customized enzymes announced today the appointment of two seasoned biotechnology executives to its Advisory Board. The new appointees are Dr. David Rozzell, founder of BioCatalytics (now Codexis) and currently CEO of Solidus Biosciences, and Dr. Ulf Bethke, COO of Miltenyi Biotec. Dr. Thomas Moser, Pontis Capital, and Harald Schuerz, Wiener Wachstumsfonds, will continue to serve on the realigned Advisory Board.

With its current members, EUCODIS Bioscience's Advisory Board will focus on providing guidance and advice in the areas of strategy, market and organization, strengthening the skills and experience of EUCODIS Bioscience's management team.

"I am extremely pleased to welcome two distinguished executives of the biotechnology industry to our Advisory Board," said Thomas Fischer, CEO EUCODIS Bioscience. "Dr. Rozzell as a successful founder and entrepreneur in the enzyme industry, and Dr. Bethke with entrepreneurial mindset and his track record in biotechnology manufacturing and operations, bring to EUCODIS Bioscience a wealth of hands-on experience and operational knowledge. Having these seasoned executives on our Advisory Board will be a tremendous asset to the Company as our customer base is growing rapidly. We will continue to expand our portfolio, and are aggressively addressing new business opportunities in the pharmaceutical, bioproducts, cosmetics, and other industries."

Dr. David Rozzell is President and CEO of Solidus Biosciences, a company providing research and analytical services to the pharmaceutical and cosmetics industry, enhancing their development productivity. Prior to joining Solidus as CEO, he was the Founder and CEO of enzyme developer BioCatalytics, which he grew to a leader in its field until the company was successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr. Rozzell was President and COO of Exogene.

Dr. Ulf Bethke is Chief Operating Officer of Miltenyi Biotec, one of Germany's most successful biotechnology companies. Before joining Miltenyi Biotec in 1994, he was responsible for the development and production of therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.

Dr. Thomas Moser is Managing Partner at Pontis Capital, an Austrian venture capital company. He has 10 years of experience as an investment manager, overseeing the whole investment life-cycle, from deal acquisition through active management of portfolio companies to financing and implementation of the exit strategy.

Harald Schuerz is CEO of Wiener Wachstumsfonds, an Austrian venture capital fund focusing on innovative, fast growing companies. Before joining Athena, he held executive positions at leading Austrian banks where he was responsible for venture capital investments and international financing.

About EUCODIS Bioscience

EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.

Customers use EUCODIS Bioscience' enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company's technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers' specific requirements.

Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or "white" biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

For more information, please visit Company contact EUCODIS Bioscience: Thomas Fischer, MBA CEO EUCODIS Bioscience Campus Vienna Biocenter II Viehmarktgasse 2 a/ 2 OG A-1030 Vienna AUSTRIA +43-1-8900804 Media contact EUCODIS Bioscience: Frank Butschbacher Investor Relations & Communications +43-650-7844940

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Receives EUR 2 Million Cash Injection to Enlarge Product Portfolio and Develop International Markets
2. EUCODIS Bioscience Appoints Thomas Fischer as New CEO
3. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
4. EUCODIS Bioscience Launches Lipase Portfolio
5. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
6. EUCODIS Bioscience Signs Research Agreement With Genencor
7. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
8. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
9. Cardio3 BioSciences Publishes the Science Basis for C-Cure(R) in JACC
10. Signum Biosciences Names Braham Shroot as Chief Executive Officer
11. YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
Post Your Comments:
(Date:12/1/2015)... Today the Allen Institute announced the opening of its ... Lake Union neighborhood, the city,s biotechnology hub. Located on ... North, the 270,000 square foot life sciences building is ... the Allen Institute for Cell Science. Paul ... Institute. "We started by building a map of the ...
(Date:12/1/2015)... Dec. 1, 2015 Oxford Finance LLC ("Oxford"), ... life sciences and healthcare services companies, today announced the ... with MDRejuvena, Inc. ("the Company"). Proceeds from the loan ... of the Company,s Rejuvaphyl™ and daily skincare products. ... the MDRejuvena brand of high potency skincare products that ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... (AFM) announces Park NX10 SICM Module, an add-on scanning ion conductance microscopy module ... power of SICM to an AFM. , Park SICM benefits virtually all materials ...
(Date:12/1/2015)... Cepheid (Nasdaq: CPHD ) today announced ... Jaffray Healthcare Conference in New York City ... its outlook for the fourth quarter of 2015 and ... longer term business model expectations. John Bishop ... to be the fastest growing company of the major ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/16/2015)... 16, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced expansion of its TDDI product portfolio ... controller and display driver integration (TDDI) solutions designed ... new TDDI products add to the previously-announced ... (WQHD resolution), and TD4322 (FHD resolution) solutions. All ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
Breaking Biology News(10 mins):